Angiotensin-converting enzyme 2 in lung diseases

The renin-angiotensin system (RAS) plays a key role in maintaining blood pressure homeostasis, as well as fluid and salt balance. Angiotensin II, a key effector peptide of the system, causes vasoconstriction and exerts multiple biological functions. Angiotensin-converting enzyme (ACE) plays a central role in generating angiotensin II from angiotensin I, and capillary blood vessels in the lung are one of the major sites of ACE expression and angiotensin II production in the human body. The RAS has been implicated in the pathogenesis of pulmonary hypertension and pulmonary fibrosis, both commonly seen in chronic lung diseases such as chronic obstructive lung disease. Recent studies indicate that the RAS also plays a critical role in acute lung diseases, especially acute respiratory distress syndrome (ARDS). ACE2, a close homologue of ACE, functions as a negative regulator of the angiotensin system and was identified as a key receptor for SARS (severe acute respiratory syndrome) coronavirus infections. In the lung, ACE2 protects against acute lung injury in several animal models of ARDS. Thus, the RAS appears to play a critical role in the pathogenesis of acute lung injury. Indeed, increasing ACE2 activity might be a novel approach for the treatment of acute lung failure in several diseases.

[1]  L. Skeggs,et al.  The biochemistry of the renin-angiotensin system. , 1980, Advances in experimental medicine and biology.

[2]  B. Uhal,et al.  Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. , 2003, The American journal of pathology.

[3]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[4]  R. Lapworth,et al.  Angiotensin-converting enzyme and its clinical significance--a review. , 1983, Journal of clinical pathology.

[5]  H. Yang,et al.  Kinetic alterations of angiotensin-II and nitric oxide in radiation pulmonary fibrosis. , 1998, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[6]  T. Parsons,et al.  Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase* , 2002, The Journal of Biological Chemistry.

[7]  N. Morrell,et al.  Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease , 2005, Respiratory research.

[8]  L. Moons,et al.  Inhibition of tissue angiotensin-converting enzyme with quinapril reduces hypoxic pulmonary hypertension and pulmonary vascular remodeling. , 1996, Circulation.

[9]  M. Yacoub,et al.  Angiotensin II activates MAPK and stimulates growth of human pulmonary artery smooth muscle via AT1 receptors. , 1999, American journal of physiology. Lung cellular and molecular physiology.

[10]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[11]  S. Abe,et al.  Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist , 2003, Thorax.

[12]  Pan‐Chyr Yang,et al.  Polymorphism of the angiotensin-converting enzyme gene affects the outcome of acute respiratory distress syndrome* , 2006, Critical care medicine.

[13]  C. Ferrario,et al.  The renin angiotensin system: importance in physiology and pathology. , 1989, Cleveland Clinic journal of medicine.

[14]  A. Nielsen,et al.  Identification of renin in resident alveolar macrophages and monocytes: HPLC and immunohistochemical study. , 1988, Journal of cell science.

[15]  S. Humphries,et al.  Angiotensin converting enzyme insertion/deletion polymorphism is associated with susceptibility and outcome in acute respiratory distress syndrome. , 2002, American journal of respiratory and critical care medicine.

[16]  L. Musgrove,et al.  Angiotensin II type-1 receptor subtype cDNAs: differential tissue expression and hormonal regulation. , 1992, Biochemical and biophysical research communications.

[17]  A. Peacock,et al.  Transpulmonary angiotensin II formation and pulmonary haemodynamics in stable hypoxic lung disease: the effect of captopril. , 1992, Respiratory medicine.

[18]  N. Hooper,et al.  The angiotensin-converting enzyme gene family: genomics and pharmacology. , 2002, Trends in pharmacological sciences.

[19]  K. Hirata,et al.  Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[20]  T. Ogihara,et al.  Deletion allele of the angiotensin-converting enzyme gene as a risk factor for pneumonia in elderly patients. , 2002, The American journal of medicine.

[21]  A. Ambergen,et al.  The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[22]  R. Maunder,et al.  Clinical risks for development of the acute respiratory distress syndrome. , 1995, American journal of respiratory and critical care medicine.

[23]  C. Sigmund,et al.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0150 Minireview: Overview of the Renin-Angiotensin System— , 2022 .

[24]  K. Mullis,et al.  Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin I-converting enzyme in the rat. , 1975, Laboratory investigation; a journal of technical methods and pathology.

[25]  Nigel M. Hooper,et al.  A Human Homolog of Angiotensin-converting Enzyme , 2000, The Journal of Biological Chemistry.

[26]  A. Molteni,et al.  Monocrotaline-Induced Pulmonary Fibrosis in Rats: Amelioration by Captopril and Penicillamine , 1985, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[27]  Prasert Auewarakul,et al.  Probable person-to-person transmission of avian influenza A (H5N1). , 2005, The New England journal of medicine.

[28]  J. Charles Jennette,et al.  Male–female differences in fertility and blood pressure in ACE-deficient mice , 1995, Nature.

[29]  Lan Zhao,et al.  Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung , 1996, British journal of pharmacology.

[30]  M. Gillespie,et al.  Lung angiotensin receptor binding characteristics during the development of monocrotaline-induced pulmonary hypertension. , 1997, Biochemical pharmacology.

[31]  Weber Kt Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. , 1997 .

[32]  M. Yacoub,et al.  Expression of pulmonary vascular angiotensin‐converting enzyme in primary and secondary plexiform pulmonary hypertension , 2000, The Journal of pathology.

[33]  M. Crackower,et al.  Angiotensin-converting enzyme 2 is an essential regulator of heart function , 2002, Nature.

[34]  A. Danchin,et al.  The Severe Acute Respiratory Syndrome , 2003 .

[35]  A. Franko,et al.  Radiation-induced pulmonary endothelial dysfunction and hydroxyproline accumulation in four strains of mice. , 1989, Radiation research.

[36]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[37]  G. Laurent,et al.  The pathogenesis of pulmonary fibrosis: is there a fibrosis gene? , 1997, The international journal of biochemistry & cell biology.

[38]  N. Morrell,et al.  Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. , 1995, The American journal of physiology.

[39]  K. Kuwano,et al.  Molecular mechanisms of pulmonary fibrosis and current treatment. , 2001, Current molecular medicine.

[40]  K. Weber Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. , 1997, Seminars in nephrology.

[41]  S. Raiden,et al.  Nonpeptide Antagonists of AT1 Receptor for Angiotensin II Delay the Onset of Acute Respiratory Distress Syndrome , 2002, Journal of Pharmacology and Experimental Therapeutics.

[42]  M. Anscher,et al.  Can Angiotensin-Converting Enzyme Inhibitors Protect against Symptomatic Radiation Pneumonitis? , 2000, Radiation research.

[43]  T. Tanaka,et al.  Tissue distribution of rat angiotensinogen mRNA and structural analysis of its heterogeneity. , 1986, The Journal of biological chemistry.

[44]  T. Jeffery,et al.  Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. , 2001, Pharmacology & therapeutics.

[45]  S. Perlman,et al.  Immunopathogenesis of coronavirus infections: implications for SARS , 2005, Nature Reviews Immunology.

[46]  B. Uhal,et al.  Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. , 2000, American journal of physiology. Lung cellular and molecular physiology.

[47]  P Corvol,et al.  Peptidyl dipeptidase A: angiotensin I-converting enzyme. , 1995, Methods in enzymology.

[48]  B. Lipworth,et al.  Haemodynamic and endocrine effects of type 1 angiotensin II receptor blockade in patients with hypoxaemic cor pulmonale. , 1997, Cardiovascular research.

[49]  Christian Drosten,et al.  Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.

[50]  W. Parks,et al.  Angiotensin converting enzyme expression in primary pulmonary hypertension. , 1996, American journal of respiratory and critical care medicine.

[51]  Y. Fung,et al.  Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. , 2004, Microvascular research.

[52]  Obi L. Griffith,et al.  The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.

[53]  J. Dubois-Randé,et al.  Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension. , 2000, American journal of respiratory cell and molecular biology.

[54]  R. Crystal,et al.  Resolution of Primary Severe Acute Respiratory Syndrome-Associated Coronavirus Infection Requires Stat1 , 2004, Journal of Virology.

[55]  M. Nicholls,et al.  The importance of the renin-angiotensin system in cardiovascular disease , 1998, Journal of Human Hypertension.

[56]  Peter B Jahrling,et al.  Exotic emerging viral diseases: progress and challenges , 2004, Nature Medicine.

[57]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[58]  C. Brambilla,et al.  Effects of captopril combined with oxygen therapy at rest and on exercise in patients with chronic bronchitis and pulmonary hypertension. , 1991, Respiration; international review of thoracic diseases.

[59]  M. Daemen,et al.  Dissociation of pulmonary vascular remodeling and right ventricular pressure in tissue angiotensin-converting enzyme-deficient mice under conditions of chronic alveolar hypoxia. , 2001, American journal of respiratory and critical care medicine.

[60]  G. Mancini,et al.  Angiotensin II type 1 receptor blocker inhibits pulmonary injury. , 2005, Clinical and investigative medicine. Medecine clinique et experimentale.

[61]  Ding-Mei Zhang,et al.  Pathogenesis of severe acute respiratory syndrome. , 2008, Chinese medical journal.

[62]  K. Robison,et al.  A Novel Angiotensin-Converting Enzyme–Related Carboxypeptidase (ACE2) Converts Angiotensin I to Angiotensin 1-9 , 2000, Circulation research.